Yanqiao U. Zhang
Haping Road No.150
Harbin, China
Harbin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 204 publications
EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 23, 2026
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: March 12, 2026
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 04, 2026
Real-World Treatment Patterns, HER2 Testing Practices, and Clinical Outcomes in HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.
Journal: Advances in therapy
Published: February 12, 2026
Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.
Journal: Cancer immunology, immunotherapy : CII
Published: February 10, 2026
Elevated CHAF1A suppresses type I interferon production and causes immunotherapy resistance in esophageal squamous cell carcinoma.
Journal: Cancer immunology research
Published: December 21, 2025
First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: December 10, 2025
Anti-PD-1 monoclonal antibody suppresses hepatitis B virus in patients with hepatocellular carcinoma.
Journal: Chinese medical journal
Published: November 11, 2025
IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses.
Journal: Cancer biology & medicine
Published: October 13, 2025
AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: September 03, 2025
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.
Journal: Nature communications
Published: August 28, 2025
Last Updated: 09/26/2026